Rischin, D., Porceddu, S. V., Day, F., Brungs, D., Christie, H. R., Jackson, J. E., Stein, B. N., Su, Y., Adams, G., Bowyer, S., Otty, Z. A., Yamazaki, N., Bossi, P., Challapalli, A., Ladwa, R., Hauschild, A., Seebach, F. A., Yoo, S., Goncalves, P. H., Fury, M. G. (2025). Phase 3 trial of adjuvant cemiplimab (cemi) versus placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.6001